证券代码：688139 证券简称：海尔生物 公告编号：2025-057 青岛海尔生物医疗股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法 承担法律责任。 本次会议由公司董事会召集，表决方式为现场投票与网络投票相结合的方式。 会议的召集、召开和表决方式符合《中华人民共和国公司法》《上海证券交易所 科创板股票上市规则》和《公司章程》的有关规定。公司董事长谭丽霞女士主持 现场会议。 （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事8人，出席8人； 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 17 日 （二） 股东大会召开的地点：青岛市高新区丰源路 280 号海尔生物医疗新兴产 业园办公楼 VIP 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 90 | | --- | --- | | 普通股股东人数 | ...

Core Viewpoint - Haier Biomedical announced the election of Liu Zhanjie as the employee representative director on the board, in compliance with the Company Law and the revised articles of association [1] Summary by Relevant Sections - **Board Composition**: The company’s board must include one employee director as per legal requirements [1] - **Election Process**: Liu Zhanjie was elected as the employee representative director through a workers' representative assembly [1] - **Announcement Reference**: Details regarding the board changes were disclosed in the announcement dated October 31 [1]

青岛海尔生物医疗股份有限公司 2025 年第一次临时股东大会会议材料 青岛海尔生物医疗股份有限公司 2025 年第一次临时股东大会会议材料 2025 年 11 月 17 日 1 青岛海尔生物医疗股份有限公司 2025 年第一次临时股东大会会议材料 青岛海尔生物医疗股份有限公司 2025 年第一次临时股东大会会议议程 时间：2025 年 11 月 17 日下午 14:00 召开地点：青岛市高新区丰源路 280 号海尔生物医疗新兴产业园办公楼 VIP 会议室 主持人：董事长 谭丽霞 会议议程： 一、主持人宣布大会开始，参会股东审议各项议案。 青岛海尔生物医疗股份有限公司 2025 年第一次临时股东大会材料目录 | 青岛海尔生物医疗股份有限公司 2025 年第一次临时股东大会会议议程 3 | | --- | | 议案一：关于变更部分回购股份用途并注销暨减少注册资本的议案 6 | | 议案二：关于公司取消监事会、变更注册资本、修订《公司章程》并办理工商变更 | | 登记的议案 7 | | 议案三：关于制定和修订相关公司治理制度的议案 9 | | 议案四：关于补选公司第三届董事会非独立董事的议案 10 | 2 青岛海尔 ...

Core Viewpoint - Haier Biomedical emphasizes the importance of user scenario requirements and is leveraging AI technology to develop intelligent solutions in the medical field [1] Group 1: AI Technology and Solutions - The company is focusing on creating intelligent management solutions for pharmacies and operating rooms, including automated medication dispensing and full-automatic liquid preparation robots [1] - Solutions for operating room behavior management have also been developed [1] Group 2: Targeted Health Management - The company is concentrating on health management for key demographics such as children and the elderly [1] - An AI-driven intelligent appointment scheduling system for vaccination clinics has been established [1]

Core Insights - The article emphasizes that ESG has evolved from an additional requirement to a core competitive necessity for Chinese enterprises, with Haier Biomedical showcasing a model of integrating ESG into sustainable growth through technology-driven practices [1][7] - Haier Biomedical's approach to ESG is rooted in its technological advancements, demonstrating that ESG can be a product of continuous innovation rather than a separate cost center [1][2] Group 1: Technological Innovation and ESG - Haier Biomedical's Eco-Drive technology has improved energy efficiency by 30%, achieving the highest efficiency level globally while maintaining operational stability [2] - The daily energy consumption of a low-temperature refrigerator has decreased from over 20 kWh in 2005 to 4.165 kWh in 2024, marking an 80% reduction over 20 years [2] - The ART intelligent control technology in stability test boxes has achieved an 80% energy savings while maintaining strict temperature control [2][3] Group 2: Economic Benefits and Efficiency - The energy savings from a new ultra-low temperature refrigerator can cover its initial purchase cost within approximately 6.7 years, saving 2.2 million yuan over ten years for a medium-sized sample library [3] - For a large sample library with 400 units, the savings can reach 11.2 million yuan over the same period, demonstrating the economic benefits of energy-efficient technologies [3] Group 3: Comprehensive ESG Integration - Haier Biomedical integrates ESG throughout its entire value chain, from procurement to manufacturing, logistics, and product lifecycle [4][5] - The company promotes "green procurement agreements" with suppliers, emphasizing the use of environmentally friendly materials and local sourcing to reduce carbon emissions [4] - The establishment of a national-level "green factory" and the largest low-temperature cold chain base in the Asia-Pacific region further exemplifies its commitment to reducing operational carbon footprints [4] Group 4: Global Impact and Innovation - Haier Biomedical has developed solar-powered vaccine refrigerators to address storage challenges in regions with inadequate electricity coverage, ensuring vaccine safety even in extreme conditions [6] - The company has expanded its services to over 160 countries, showcasing Chinese innovation in global public health solutions [6] - The launch of the "green ecological co-construction initiative" at the Import Expo signifies a collaborative approach to sustainability within the industry [6] Group 5: Lessons for the Industry - Haier Biomedical's ESG practices provide a replicable model for Chinese listed companies, emphasizing the integration of technological innovation with business growth [7] - The company's journey illustrates that ESG is not merely a reporting obligation but a fundamental aspect of operational strategy and product development [7] - The deep integration of ESG into business operations positions Haier Biomedical favorably in attracting long-term investors in the capital market [7]

Group 1: Haier Biomedical - Haier Biomedical showcased multiple technological products and digital solutions aimed at addressing practical needs in research and laboratory settings, including a super-speed centrifuge that achieves speeds of 100,000 RPM, filling a domestic gap in the field [2] - The company introduced a fully enclosed automated cell expansion system that enhances consistency and reproducibility in experiments by automating the cell culture process and ensuring data traceability [2] - Haier's biological sample management solution utilizes NAIT recognition technology for automated management in ultra-low temperature environments, significantly reducing labor costs and improving data accuracy [2] - The company presented energy-efficient products, such as ultra-low temperature storage boxes, which reportedly consume 50% less electricity than traditional models [2][3] - Haier Biomedical's products and solutions are now available in over 160 countries and regions, with a commitment to advancing technology development based on user challenges in real-world applications [3] Group 2: Medtronic - Medtronic announced the full localization of its product line in China, showcasing its "fully localized innovative solutions" at the expo, which includes core products for tumor treatment [5] - The company highlighted its Leksell Gamma Knife Elekta Esprit, which supports millimeter-level precision in radiation therapy, and the Elekta Evo platform that integrates AI imaging technology to enhance operational efficiency [5][6] - Medtronic's Elekta Unity system has treated over 10,000 patients since its introduction in China, covering more than 40 types of tumors and generating over 160 related clinical research papers [5][7] - The company aims to support China's "Healthy China 2030" initiative by promoting high-quality radiation therapy technology [7] Group 3: Fosun Pharma - Fosun Pharma presented various innovative drugs and high-end medical devices at the expo, focusing on improving treatment outcomes and quality of life for patients with diseases such as tumors and neurological disorders [8] - The company introduced the Da Vinci surgical robot and CAR-T cell therapy product Yikaida, which has been included in over 110 health insurance plans, enhancing accessibility for lymphoma patients [9] - Fosun's Marie particle therapy system, approved by the FDA, offers a compact design for rapid deployment in hospitals, improving treatment precision for lung and breast tumors [8][9] - The company is actively promoting the application of artificial intelligence in healthcare, with platforms designed for drug decision-making and clinical trial predictions [10]

Core Viewpoint - Haier Biomedical is leading the green transformation in the life sciences industry by launching innovative technologies and establishing a collaborative ecosystem for sustainable development [1][5]. Group 1: Technological Innovation - Haier Biomedical has established a foundation of green and technological advancement since 2005, breaking a 30-year foreign monopoly with the development of China's first ultra-low temperature storage box [2]. - The newly launched Eco-Drive ultra-green technology improves energy efficiency by 30% compared to the highest current industry standards, achieving the top rank in global energy efficiency [2]. - The AI-driven temperature and humidity control system for drug stability has increased energy efficiency by 80%, saving nearly 40,000 yuan in electricity costs annually for ten devices [3]. Group 2: Industry Standards and Certifications - Haier Biomedical has received multiple certifications, including 44 Energy Star certifications and 116 energy-saving environmental protection certificates, showcasing its commitment to sustainability [4]. - The company has been recognized in the S&P Global "Sustainability Yearbook (China Edition)" for three consecutive years, highlighting its leadership in green practices within the biomedicine sector [4]. Group 3: Collaborative Ecosystem - The company has initiated a green ecological co-construction initiative in collaboration with authoritative organizations like Ernst & Young and UL, aiming to promote green standards and practices across the industry [5][6]. - Haier Biomedical's solar vaccine refrigerator solution serves over 45 million children annually in more than 80 countries along the Belt and Road, addressing vaccine storage challenges in regions with inadequate power supply [7]. Group 4: Global Market Performance - In the first three quarters of this year, Haier Biomedical's overseas market revenue reached 634 million yuan, reflecting a year-on-year growth of 20.18%, driven by its green technology [7].

Core Insights - The China International Import Expo (CIIE) serves as a significant platform for showcasing innovation and collaboration, with Haier Biomedical presenting multiple cutting-edge technologies and solutions this year [1][3] Group 1: Breakthrough Technologies and Innovations - Haier Biomedical introduced the first domestic ultra-speed centrifuge capable of exceeding 100,000 RPM, filling a gap in high-end centrifuge equipment in China and positioning the country as the third globally to master this technology [3] - The company also launched a fully automated closed cell expansion system, designed for cell culture and exosome preparation, which enhances efficiency and reduces contamination risks [3] - The AI-driven low-temperature storage management solution, based on original -86°C NAIT recognition technology, streamlines sample management processes, significantly improving operational efficiency for researchers [5] Group 2: Green Development and Sustainability - Haier Biomedical emphasizes green development, showcasing energy-efficient products that save 50% in daily electricity consumption compared to traditional models, equating to an annual saving of 2,843 kWh [6] - The company has established a comprehensive green value chain covering procurement, manufacturing, logistics, and product lifecycle, with 44 product models receiving Energy Star certification [6] - Haier Biomedical's solar-powered vaccine refrigerators and mobile laboratories have been deployed in over 80 countries along the Belt and Road Initiative, contributing to the "Green Silk Road" [6] Group 3: Global Market Expansion - The company has adopted a localized strategy, with products and solutions reaching over 160 countries and benefiting more than 100 million users globally [7][8] - Haier Biomedical's participation in the CIIE highlights its commitment to high-level openness and innovation in the life sciences sector, with a focus on ecological integration and resource efficiency [8]

Core Viewpoint - Haier Biomedical has achieved a significant breakthrough in ultra-high-speed centrifuge technology, marking a transition from reliance on imports to self-sufficiency in high-end life science instruments in China [1][3]. Group 1: Product Development - The newly launched ultra-high-speed centrifuge can reach a maximum speed exceeding 100,000 RPM, filling a gap in the domestic market for ultra-high-speed centrifuge equipment [1][3]. - The centrifuge's performance in terms of speed stability, data security, and rotor compatibility has reached the advanced level of international counterparts [3][4]. Group 2: Market Context - The demand for ultra-high-speed centrifuges is increasing due to advancements in cell therapy, vaccine development, and pharmaceutical processes, which require higher efficiency than conventional centrifuges can provide [3]. - As of 2025, leading international brands are projected to hold approximately 62% of the centrifuge market in China, highlighting the importance of domestic technological self-reliance [3]. Group 3: Application and Impact - The ultra-high-speed centrifuge is designed to enhance particle separation and purity control, which is crucial for the isolation and purification of microscopic samples such as viral particles and natural proteins [4]. - The device has broad application potential across various fields, including materials science and cell engineering, providing significant support for safe and effective sample preparation [4].

Core Insights - The high-quality development of the health industry is crucial for meeting people's needs and driving economic structural upgrades [1] - The eighth China International Import Expo (CIIE) showcased Haier Biomedical's innovations, marking a significant step in China's life sciences industry [1][2] - Haier Biomedical's breakthroughs in high-speed centrifuge technology represent a leap from dependence on foreign technology to self-reliance and global output [3][4] Technological Breakthroughs - Haier Biomedical has developed China's first 100,000 RPM ultra-speed centrifuge, breaking the long-standing international monopoly in this field [3][4] - The global market for ultra-speed centrifuges is projected to grow from $1.536 billion in 2024 to $3.276 billion by 2031, highlighting the increasing demand [3] - The company has achieved full autonomy in three core technologies: ultra-speed vacuum motors, flexible drive technology, and secondary ultra-vacuum technology [4] AI and Smart Solutions - The integration of AI in life sciences is transforming competition from equipment performance to data-driven smart ecosystem competition [6] - Haier Biomedical's smart sample management solution utilizes innovative tracking technology to enhance efficiency in sample handling [6][7] - The company's future laboratory solutions aim to create a highly efficient collaborative chain from sample preparation to result output [7] Global Expansion - Haier Biomedical's overseas revenue grew by over 30% in the first half of 2025, with a more than 200% increase in overseas market share from 2019 to 2024 [9] - The company has established localized operations in 18 countries, including the UK, the Netherlands, and the US, to better address global customer needs [9] - In Europe, Haier Biomedical's products have gained recognition, with significant installations in prestigious institutions like the British Biobank and Halle University in Germany [10] Strategic Collaborations - Haier Biomedical is collaborating with Vietnamese healthcare institutions to implement a comprehensive digital solution for medication management [11] - The company is also enhancing health capabilities in Africa through various projects, including the establishment of a full-scene laboratory for disease control [11] - These initiatives reflect Haier Biomedical's transition from a mere equipment provider to a solution-defining entity in the global market [11][12]